Faron Pharmaceuticals: Research program progressing as planned
We have updated our assessment of the progress of Faron’s research program and based on that, the commercial potential of the company's drug candidates. The individual studies of the research program have largely progressed as we expected and the changes to our model are moderate in size. The most important change is the increased number of blood cancer patients who could potentially benefit from bexmarilimab (BEX). However, since October, the share price has increased more than our fair value, which weakens the share’s risk/return ratio. We believe the share is close to the upper limit of its fair value range.
Faron Pharmaceuticals
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. Faron is based in Turku, Finland.
Read more on company pageKey Estimate Figures09.01.2023
2021 | 22e | 23e | |
---|---|---|---|
Omsætning | 0,0 | 0,0 | 0,0 |
vækst-% | |||
EBIT (adj.) | -21,1 | -22,1 | -0,8 |
EBIT-% (adj.) | -527.700,00 % | -551.975,00 % | -20.292,50 % |
EPS (adj.) | -0,40 | -0,37 | -0,02 |
Udbytte | 0,00 | 0,00 | 0,00 |
Udbytte % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |